Ketamine for Depression

 

Ketamine for Depression Summary

Clinical research on ketamine for depression highlights its rapid-acting antidepressant effects. A 2024 "Bio-K" study found that after only three infusions over 11 days, 52% of patients with severe depression achieved remission. A 2025 SUSTAIN study followed patients for 6.5 years and found no new safety concerns or long term side effects, with side effects being limited to the day of the dosing.

Note: Ketamine has not yet officially been approved for treating depression by the FDA, so its use is considered "off-label" and should only be done under supervision of a physician. The only approved use for depression is through use of nasal spray Ketamine.

1) Mechanism of Action

Ketamine is used as a rapid-acting antidepressant for treatment-resistant depression and severe depressive episodes.

  • NMDA receptor antagonism in glutamatergic neurons
  • Relative increase in AMPA receptor signaling
  • Activation of BDNF (brain-derived neurotrophic factor)
  • Activation of mTOR pathways
  • Rapid synaptogenesis and neuroplasticity in prefrontal/limbic circuits

These effects help restore disrupted neural connectivity involved in mood regulation.

2) Clinical Indications

  • Treatment-resistant major depressive disorder (TRD)
  • Severe depressive episodes
  • Acute suicidal ideation
  • Depression with inadequate response to standard antidepressants
  • Intranasal esketamine is FDA-approved for certain forms of treatment-resistant depression, IV ketamine therapy is off-label use only under supervision of a physician.

3) Clinical Effects

  • Reduction in depressive symptoms
  • Decreased suicidal ideation
  • Improved mood and motivation
  • Improved emotional processing
  • Timeline: Noticeable Results - within hours, Peak Results - ~24 hours, Total Duration 1-2 weeks for most.
  • Note: Since effects are often temporary, protocols usually involved repeated dosing sessions

4) Methods of Administration

Typically administered in specialized clinical settings with monitoring.

  • Intravenous ketamine infusion
  • Intranasal esketamine

Treatment is commonly combined with antidepressant therapy, psychotherapy, and psychiatric follow-up.

5) Potential Advantages

  • Rapid onset of action
  • Effective in treatment-resistant depression
  • Rapid reduction of suicidal ideation
  • Option when multiple medications fail
  • Especially useful during psychiatry crises

6) Limitations and Risks

  • Short duration of benefit; may require repeated treatments
  • Cost and access limitations
  • Potential for misuse or dependence
  • Usually provided under strict medical supervision with clear risk mitigation

7) Adverse Effects

Common acute side effects (often resolving within 1–2 hours):

  • Dissociation
  • Perceptual disturbances
  • Dizziness
  • Nausea
  • Sedation
  • Transient increases in blood pressure

8) Current Clinical Role

Ketamine is typically considered for:

  • Treatment-resistant depression
  • Severe depressive symptoms
  • Acute suicidal ideation requiring rapid intervention

Care is usually delivered through specialized psychiatric programs or ketamine clinics.